Skip to main content Accessibility help
  • Get access
    Check if you have access via personal or institutional login
  • Cited by 5
  • Print publication year: 2010
  • Online publication date: December 2010

19 - Urinary retention

from Section 3 - Specific conditions


Sexual function is recognized as an important factor determining quality of life and dysfunction in neurological patients may significantly add to the burden of their disease. Any disruption in the sexual response cycle results in sexual dysfunction (SD). Laboratory testing should be tailored according to patient symptoms and risk factors. Fasting glucose and lipid profile may be measured to assess atherosclerotic risk factors for erectile dysfunction (ED). Oral drugs should be considered as first-line therapy for neurogenic ED. There are fewer evidence-based therapeutic options for treatment of female SD. However it is an area of increasing interest and marketing of therapies by pharmaceutical companies. Therapies relate to treatment of sexual desire, arousal, orgasm and/or sexual pain. The term hypoactive sexual desire disorder (HSDD) is used to describe low sexual desire and distress, and many therapies aim to address this aspect of female sexual function.


1. Hahn K, Ebersbach G. Sonographic assessment of urinary retention in multiple system atrophy and idiopathic Parkinson's disease. Mov Disord 2005;20:1499–502.
2. Ito T, Sakakibara R, Yasuda K, et al. Incomplete emptying and urinary retention in multiple-system atrophy: when does it occur and how do we manage it? Mov Disord 2006;21:816–23.
3. Lapointe SP, Rivet C, Goulet O, Fekete CN, Lortat-Jacob S. Urological manifestations associated with chronic intestinal pseudo-obstructions in children. J Urol 2002;168(4 Pt 2):1768–70.
4. Mousa H, Hyman PE, Cocjin J, Flores AF, Di Lorenzo C. Long-term outcome of congenital intestinal pseudoobstruction. Dig Dis Sci 2002;47:2298–305.
5. Vargas JH, Sachs P, Ament ME. Chronic intestinal pseudo-obstruction syndrome in pediatrics. Results of a national survey by members of the North American Society of Pediatric Gastroenterology and Nutrition. J Pediatr Gastroenterol Nutr 1988;7:323–32.
6. Wiseman OJ, Fowler CJ, Landon DN. The role of the human bladder lamina propria myofibroblast. BJU Int 2003;91:89–93.
7. Knox S. Psychogenic urinary retention after parturition resulting in hydronephrosis. Br Med J 1960;2:1422–4.
8. Margolis GJ. A review of literature on psychogenic urinary retention. J Urol 1965;94:257–8.
9. Allen TD. Psychogenic urinary retention. South Med J 1972;65:302–4.
10. Barrett DM. Psychogenic urinary retention in women. Mayo Clin Proc 1976;51:351–6.
11. Montague DK, Jones LR. Psychogenic urinary retention. Urol 1979;13:30–5.
12. Bird JR. Psychogenic urinary retention. Psychother Psychosom 1980;34:45–51.
13. Bassi P, Zattoni F, Aragona F, et al. La retention psychogene d'urine chez la femme: aspects diagnostiques et therapeutiques. J d'Urologie 1988;94:159–62.
14. Moore T. Bladder-neck obstruction in women. Proc R Soc Med 1953;46:558–64.
15. Raz S, Smith RB. External sphincter spasticity syndrome in female patients. J Urol 1976;115:443–6.
16. Fowler CJ, Kirby RS. Abnormal electromyographic activity (decelerating bursts and complex repetitive discharges) in the striated muscle of the urethral sphincter in 5 women with persisting urinary retention. Br J Urol 1985;57:69–70.
17. Fowler CJ, Christmas TJ, Chapple CR, et al. Abnormal electromyographic activity of the urethral sphincter, voiding dysfunction, and polycystic ovaries: a new syndrome? BMJ 1988;297:1436–8.
18. Fowler CJ, Kirby RS, Harrison MJ. Decelerating burst and complex repetitive discharges in the striated muscle of the urethral sphincter, associated with urinary retention in women. J Neurol Neurosurg Psychiatry 1985;48:1004–9.
19. Butler WJ. Pseudomyotonia of the periurethral sphincter in women with urinary incontinence. J Urol 1979;122:838–40.
20. Jensen D, Stien R . The importance of complex repetitive discharges in the striated female urethral sphincter and male bulbocavernosus muscle. Scand J Urol Nephrol Suppl 1996;179:69–73.
21. FitzGerald MP, Blazek B, Brubaker L. Complex repetitive discharges during urethral sphincter EMG: clinical correlates. Neurourol Urodyn 2000;19:577–83.
22. Fowler CJ, Dasgupta R. Electromyography in urinary retention and obstructed voiding in women. Scand J Urol Nephrol Suppl 2002:55–8.
23. O'Connell HE, Hutson JM, Anderson CR, Plenter RJ. Anatomical relationship between urethra and clitoris. J Urol 1998;159:1892–7.
24. O'Connell HE, DeLancey JO. Clitoral anatomy in nulliparous, healthy, premenopausal volunteers using unenhanced magnetic resonance imaging. J Urol 2005;173:2060–3.
25. Swinn MJ, Wiseman O, Lowe E, Fowler CJ. The cause and natural history of isolated urinary retention in young women. J Urol 2002;167:151–6.
26. Wiseman OJ, Swinn MJ, Brady CM, Fowler CJ. Maximum urethral closure pressure and sphincter volume in women with urinary retention. J Urol 2002;167:1348–51.
27. Edwards L, Malvern J. The urethral pressure profile: theoretical considerations and clinical application. Br J Urol 1974;46:325–36.
28. Wiseman OJ, Swinn MJ, Brady CM, Fowler CJ. Maximum urethral closure pressure and sphincter volume in women in retention. J Urol 2002;167:367–71.
29. de Groat WC, Fraser MO, Yoshiyama M, et al. Neural control of the urethra. Scand J Urol Nephrol Suppl 2001;35:35–43.
30. Fowler CJ, Griffiths D, de Groat WC. The neural control of micturition. Nat Rev Neurosci 2008;9:453–66.
31. Kavia R, Dasgupta R, Critchley H, Fowler C, Griffiths D. A functional magnetic resonance imaging study of the effect of sacral neuromodulation on brain responses in women with Fowler's syndrome. BJU Int 2010;105:366–72.
32. Swinn MJ, Kitchen ND, Goodwin RJ, Fowler CJ. Sacral neuromodulation for women with Fowler's syndrome. Eur Urol 2000;38:439–43.
33. DasGupta R, Fowler CJ. Urodynamic study of women in urinary retention treated with sacral neuromodulation. J Urol 2004;171:1161–4.
34. Dasgupta R, Critchley HD, Dolan RJ, Fowler CJ. Changes in brain activity following sacral neuromodulation for urinary retention. J Urol 2005;174:2268–72.
35. Verhamme KM, Sturkenboom MC, Stricker BH, Bosch R. Drug-induced urinary retention: incidence, management and prevention. Drug Saf 2008;31:373–88.
36. Malinovsky JM, Le Normand L, Lepage JY, et al. The urodynamic effects of intravenous opioids and ketoprofen in humans. Anesth Analg 1998;87:456–61.
37. Kuipers PW, Kamphuis ET, van Venrooij GE, et al. Intrathecal opioids and lower urinary tract function: a urodynamic evaluation. Anesthesiology 2004;100:1497–503.
38. Petros JG, Realica R, Ahmad S, Rimm EB, Robillard RJ. Patient-controlled analgesia and prolonged ileus after uncomplicated colectomy. Am J Surg 1995;170:371–4.
39. Pandita RK, Pehrson R, Christoph T, Friderichs E, Andersson KE. Actions of tramadol on micturition in awake, freely moving rats. Br J Pharmacol 2003;139:741–8.
40. Pehrson R, Andersson KE. Tramadol inhibits rat detrusor overactivity caused by dopamine receptor stimulation. J Urol 2003;170:272–5.
41. Meyboom RH, Brodie-Meijer CC, Diemont WL, van Puijenbroek EP. Bladder dysfunction during the use of tramadol. Pharmacoepidemiol Drug Saf 1999;8(Suppl 1):S63–4.
42. Matsumoto S, Levendusky MC, Longhurst PA, Levin RM, Millington WR. Activation of mu opioid receptors in the ventrolateral periaqueductal gray inhibits reflex micturition in anesthetized rats. Neurosci Lett 2004;363:116–9.
43. Panicker J, Khan S, Kessler T, et al. The possible role of opiates in women with urinary retention. Observations from a prospective clinical study. 39th Annual Meeting of the International Continence Society (ICS). San Francisco; 2009.
44. Datta SN, Chaliha C, Singh A, et al. Sacral neurostimulation for urinary retention: 10-year experience from one UK centre. BJU Int 2008;101:192–6.
45. Van Voskuilen AC, Oerlemans DJ, Weil EH, van den Hombergh U, van Kerrebroeck PE. Medium-term experience of sacral neuromodulation by tined lead implantation. BJU Int 2007;99:107–10.
46. Elhilali MM, Khaled SM, Kashiwabara T, Elzayat E, Corcos J. Sacral neuromodulation: long-term experience of one center. Urology 2005;65:1114–7.
47. De Ridder D, Ost D, Bruyninckx F. The presence of Fowler's syndrome predicts successful long-term outcome of sacral nerve stimulation in women with urinary retention. Eur Urol 2007;51:229–33.
48. Elneil S, Khan S, Kavia RBCet al. Two-stage sacral neuromodulation for chronic urinary retention in women: outcome and response prognostic factors. In prepration.
49. Chen ML, Shen B, Wang Jet al. Influence of naloxone on inhibitory predendal-to-bladder reflex in cats. Exp Neurol 2010;224:282–91.
50. Datta SN, Kavia RB, Gonzales G, Fowler CJ. Results of double-blind placebo-controlled crossover study of sildenafil citrate (Viagra) in women suffering from obstructed voiding or retention associated with the primary disorder of sphincter relaxation (Fowler's syndrome). Eur Urol 2007;51:489–97.
51. Fowler CJ, Betts CD, Christmas TJ, Swash M, Fowler CG. Botulinum toxin in the treatment of chronic urinary retention in women. Br J Urol 1992;70:387–9.
52. Jonas U, Fowler CJ, Chancellor MB, et al. Efficacy of sacral nerve stimulation for urinary retention: results 18 months after implantation. J Urol 2001;165:15–9.